1 / 18

ADCs: the opportunity

ADCs: the opportunity . Barry Heavey, Head of Life Sciences IDA Ireland June 20 th , 2014. ADC market opportunity. Herceptin: Launched 1998 patent expiration 2014 Controversy over price/efficacy Mylan & Biocon Biosimilars in India Kadcyla : Herceptin ADC

vadin
Download Presentation

ADCs: the opportunity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ADCs: the opportunity Barry Heavey, Head of Life Sciences IDA Ireland June 20th, 2014

  2. ADC market opportunity • Herceptin: • Launched 1998 • patent expiration 2014 • Controversy over price/efficacy • Mylan& BioconBiosimilars in India • Kadcyla: • Herceptin ADC • 80% of US oncologists are prescribing only 9 months after FDA approval • $100M in Q1 2014 • Peak sales estimate $2-5bn

  3. ADC market opportunity • Brentuximab • Millenium/Takeda pipeline antibody • 2000-2010: Failed to show efficacy in clinical trials for Hodgkins Lymphoma • Brentuximab-vedotin (ADCetris) • Partnership with Seattle Genetics to develop ADC version • 34% complete remission, 40% partial remission • Accelerated approval 2012 • 2015 sales target €420M

  4. ADC market opportunity • “Biobetters” of existing Mabs: kadcyla • “Reactivate” shelved Mabs: Adcetris • Precedents for strong efficacy, fast track status • Part of overall strong momentum in oncology • €42Bn chemotherapy market growing through innovation • Regulators/payors/clinicians getting familiar with ADC technology • All major pharma companies now developing ADCs • 2013: 100 ADCs in clinical trials

  5. Selected ADCs in clinical development

  6. ADC market opportunity • Technology maturing • VC backing for novel technology • linker/conjugation chemistry/site-specific conjugation/payload • Investment in supporting services • Specialised CMOs – linkers, conjugation, high containment FF • Specialised CROs for QA/QC? • Investment by equipment/technology companies • Process engineering for conjugation • Improved containment tech • Improved analytics (process and product) • Single use ADC mfng systems • Specialised conferences, industry working groups etcetc • Broad investment helps mitigate technology risk

  7. ADC Global Manufacturing Capabilities Future location …

  8. Case study: Adcetris supply chain

  9. ADCs: B-2-B collaboration essential

  10. The opportunity for Ireland • Ireland is winning high value manufacturing FDI • Biotech DS/DP • High potency API/formulation • Single product sites transitioning to multiproduct sites • Combination products: drug-device combos • Global release testing • Packaging • Responsibility for management of complex supply chains • VC funds being attracted to Ireland • Can attract innovator companies • Technology providers in Ireland • Indigenous: PM, DPS, Prosys… • MNC: GE, Waters, PPD, Millipore… • Manufacturing a priority area for state investment (R&D grants)

  11. $2bn in Recent Investment Wins July. 2013 Establishing packaging, quality and supply chain function in Dublin Employs > 100 Feb. 2013 $44m investment in Biotech campus Employs > 500 Aug. 2013 $300M investment in 400,000ft2 biotech drug substance facility April. 2014 Global supply chain, quality fill finish & packaging. 250 jobs $100M April. 2014 Manufacturing of biologic device combination product. 270 jobs $100M Apr. 2012 $500m investment in two strategic sites Respiratory and sterile fill finish Employs > 700 Jan. 2012 $350m investment Manufacturing & development 200 new jobs June. 2011 Manufacturing plant $50m/100 jobs Apr. 2012 $200m investment Employs > 300 Apr. 2012 New Biotech facility in Cork $420m/200 jobs

  12. Biopharma Cluster In Ireland • More than 5,000 people employed in Biotech development and manufacturing in 2014 • 7% employment growth per annum since 2009 • NIBRT provided training in biopharmamanufacturing to 2,000 people in 2013

  13. Recent supply chain management projects in pharma

  14. Why Ireland for biopharma FDI? • 9 of the world’s top 10 Pharmaceutical companies • 83 plants - 33 FDA approved. • 17 Biopharmaceutical plants • Exports €55 billion in 2012. • 24,500 people directly employed plus 24,500 indirect • Strong regulatory track record – FDA/IMB • National Institute for Bioprocessing, Research and Training (NIBRT) • Construction/engineering capacity and capability. • Strategic sites. • Cluster development • Government R&D support through IDA and SFI

  15. Developing an “ADC Cluster” • IDA committed to supporting ADC investments through grant aid • Biopharma companies: grants for in-house process R&D • Supplier companies: grants for new product/service development

  16. Developing an “ADC Cluster” • IDA committed to supporting ADC investments through grant aid • Biopharma companies: grants for in-house process R&D • Supplier companies: grants for new product/service development Government spend on R&D (€800M in 2012)

  17. Developing an “ADC Cluster” • IDA committed to supporting ADC investments through grant aid • Biopharma companies: grants for in-house process R&D • Supplier companies: grants for new product/service development • Indigenous companies – support from Enterprise Ireland • Opportunities for B-2-B collaboration • SFI/EI supports for industry academic collaborations/consortiums • NIBRT as a neutral venue/pilot scale test-bed/showcase facility • R&D programs = marketing collateral for FDI • Networking/mobilising the sector • Biopharma industry tech group • Establish Subgroup on ADCs? • Spot opportunities for B-2-B collaboration • Develop proposals for publically funded research programs

  18. To learn more log on to idaireland.com +353 1 6034285 Barry.heavey@ida.ie

More Related